CORE--STEM CELL FACILITY

1998年，癌症中心执行委员会同意计划建立干细胞生物学中心。这个共享资源将根据研究者的要求提供高质量的小鼠和人类造血干细胞和祖细胞。这种途径对于促进和扩展参与转化癌基因研究的研究人员的工作、基因突变的生物学意义、新的基因治疗递送载体的效用以及理解粘附、信号传导和细胞发育的正常细胞过程是无价的。Core还将协助癌症中心成员从事转化和临床研究，证明评估正在研究的特定干预/治疗对血液系统的影响所需的技术专长。现有的检测方法将使研究者能够确定：在培养中对人类造血干细胞和祖细胞生长的影响；细胞表面蛋白显示变化的免疫组化分析；利用RT-PCR、代表性分析（RDA）和高密度DNA膜阵列对基因表达的影响。干细胞生物学核心将由医学、病理学和检验医学教授ALAN Gewirtz博士指导，他因在干细胞生物学和治疗学方面的专业知识而获得认可，并获得多项NCI资助（RAID， PO1和R01）。通过他作为基础、转化和临床研究者的个人研究经验，Gewirtz博士确定了这样一个核心的必要性，以便进行创新研究。具有这种供资核心的PO1的高级研究人员的经验进一步加强了这一点，大大提高了有关研究的质量和及时性。Gewirtz博士的长期合作伙伴Mariusz Ratajczak医学博士将担任该设施的技术总监。在一起,Drs。Gewirtz和Ratajczak在造血干细胞的分离和培养方面有30多年的经验。获得同行评审资助的癌症中心成员的使用量预计将占总使用量的70%，癌症中心成员的总使用量预计将占总使用量的90%。

In 1998, the Cancer Center Executive Committee agreed to plan the establishment of a Stem Cell Biology Core. This Shared Resource will provide access to high quality murine and human hematopoietic stem and progenitor cells based on investigator requests. Such access is invaluable in facilitating and extending the work of investigators involved in the study of transforming oncogenes, the biologic significance of gene mutations, the utility of new gene therapy delivery vectors and understanding the normal cellular processes of adhesion, signaling and cell development. The Core will also assist Cancer Center members engaged in translational and clinical research by proving the technical expertise needed to evaluated the effects of a given intervention/therapy under study on the hematologic system. Available assays will provide the investigator with the ability to determine: the effects on human hematopoietic stem and progenitor cell growth in culture; immunohistochemical analysis of changes in cell surface protein display; and effects on gene expression using RT-PCR, representational analysis (RDA) and high density DNA membrane arrays. The Stem Cell Biology Core will be directed by ALAN Gewirtz, MD, Professor of Medicine and Pathology and Laboratory Medicine, who is recognized for his expertise in stem cell biology and therapeutics and has several NCI grants (RAID, PO1 and R01). Through his personal research experience as a basic, translational and clinical investigator, Dr. Gewirtz, identified the need for such a core in order to conduct innovative research. This was further reinforced by the experience of senior investigators on a PO1 that had a funded core of this type, which has greatly enhanced the quality and timeliness of the related research. Mariusz Ratajczak, MD, PhD, a long-time collaborator of Dr. Gewirtz, will assume the role of Technical Director of the facility. Together, Drs. Gewirtz and Ratajczak have more than 30 years experience in the isolation and culture of hematopoietic stem cells. Usage by Cancer Center members with peer reviewed funding is expected to be 70% of overall usage and total usage by Cancer Center members is expected to be 90% of overall usage.